Sanofi

Gilbert Marciniak

Bertrand Vivet

Baptiste Ronan

Fabrice Viviani

Bruno Filoche-Romme

Maurice Brollo

Jean-Francois Nave

Annie Clauss

Youssef El-Ahmad

Nicolas Muzet

Frank Halley

Laurent Schio

Youssef El Ahmad

Jean-Philippe Letallec

Karl Andreas Karlsson

Andre Zimmermann

Christophe Glaess

Eric Bacque

Alain Jean Braun

Eric Nicolai

Olivier Crespin

Cecile Pascal

Philip Janiak

Yann Foricher

Cécile Pascal

Axel Ganzhorm

Véronique Zerr

André Seyer

Jean-François Nave

Youssef El-ahmad

Bruno Filoche-RommÉ

André Zimmermann

Alain Braun

The invention relates to the novel products of formula (I): with p, q=0, 1 or 2; R1=phenyl, pyridyl; &#x2014;(CH)&#x2014;Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; &#x2014;SO&#x2014;Rb; &#x2014;CO&#x2014;Re; m=1 or 2; Ra=aryl, heteroaryl, &#x2014;CO-cycloalkyl, &#x2014;CO-heterocycloalkyl, &#x2014;CO&#x2014;Rb, &#x2014;C(Rb)&#x2550;N&#x2014;ORc, &#x2014;CORd, &#x2014;CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CHor CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is and the isomer of configuration R,R these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.

2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof

The invention relates to the novel products of formula (I) with p, q=0, 1 or 2; R1=phenyl, pyridyl; &#x2014;(CH)&#x2014;Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; &#x2014;SO&#x2014;Rb; &#x2014;CO&#x2014;Re; m=1 or 2; Ra=aryl, heteroaryl, &#x2014;CO-cycloalkyl, &#x2014;CO-heterocycloalkyl, &#x2014;CO&#x2014;Rb, &#x2014;C(Rb)&#x2550;N&#x2014;ORc, &#x2014;CO 2 Rd, &#x2014;CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF 3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CHor CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is (Formula 1a) and the isomer of configuration R,R (Formula 1b) these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments. 

2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and Ris a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof. 

Pyrimidinone derivatives as antimalarial agents

The invention relates to bicyclic heterocyclic derivatives of general formula (I) to a process for preparing them and to the therapeutic use thereof. 

Pyrimidooxazocine derivatives as mTOR-inhibitors

The invention relates to compounds of the formula:  or their racemic, enantiomeric or diastereoisomeric isomers, or pharmaceutically acceptable salts of the compounds of formula I or the racemic, enantiomeric or diasteroisomeric isomers.

1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof

A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.

Therapeutic applications in the cardiovascular field of quinazolinedione derivatives

The invention relates to a product of formula (I) where R1, R2, R3, and R4 are as defined herein, the therapeutic use of the product, a process to make the product, and a pharmaceutical composition comprising the product.

2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof

The subject matter of the present invention is the use of compounds of formula (I) in the form of a base, a hydrate or a solvate, or of mixtures thereof, as a medicament or for preparing a medicament intended for the treatment and/or prevention of disorders associated with the central nervous system (abbreviated to CNS) and/or associated with the peripheral nervous system (abbreviated to PNS). 

Therapeutic uses of quinazolinedione derivatives

The subject matter of the invention is quinazolinedione derivatives of formula (I), methods for obtaining same and therapeutic uses thereof, such as cancer, diabetes, muscle diseases, bone diseases, cardiovascular diseases, central nervous system diseases, peripheral nervous system diseases, inter alia.

Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof

The invention relates to quinazolinedione derivatives of the general formula (I): wherein A, R, R, R, R, m, n, p, p', and r are as defined herein, processes for the preparation thereof and their therapeutic applications.

Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof

Growing community of inventors

Paris, France

Gilbert Marciniak